KORTUC, a company developing a biologically driven intratumoral radiosensitization approach, announced that it will exhibit at ESTRO 2026, to be held in Stockholm, Sweden, from May 15–19, 2026. This will mark the company’s first exhibition in Europe. KORTUC’s approach is designed to make tumors more sensitive to radiotherapy while integrating into existing clinical workflows. In addition to enhancing treatment response, the technology may support organ-preservation strategies and has the potential to impact the tumor immune response. The company’s clinical development includes a registrational Phase 2 trial in breast cancer, with complete response as a key endpoint and near full enrollment. KORTUC is also advancing a rectal cancer program focused on treatment strategy and organ preservation, as well as a global Phase 1/2 cervical cancer study initiated in Thailand, evaluating progression-free survival. Through its participation in ESTRO 2026, KORTUC aims to engage with the European radiation oncology community and explore opportunities for clinical and academic collaboration. KORTUC will be exhibiting at Booth C05:76. https://www.estro.org/Congresses/ESTRO-2026
The release as fetched from its publisher. kortuc.com ↗